| Identification | Back Directory | [Name]
3-(6,7-dimethoxyquinazolin-4-yloxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide | [CAS]
1315330-17-6 | [Synonyms]
TL02-59
TL-02-59,Inhibitor,Lyn,Apoptosis,leukemia,inhibit,acute,Src,orally,AML,TL02-59,TL02 59,TL0259,Hck,myelogenous,Fgr
3-(6,7-dimethoxyquinazolin-4-yloxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide
Benzamide, 3-[(6,7-dimethoxy-4-quinazolinyl)oxy]-N-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl- | [Molecular Formula]
C32H34F3N5O4 | [MDL Number]
MFCD29991221 | [MOL File]
1315330-17-6.mol | [Molecular Weight]
609.64 |
| Chemical Properties | Back Directory | [Boiling point ]
630.5±55.0 °C(Predicted) | [density ]
1.290±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 125 mg/mL (205.04 mM) | [form ]
Solid | [pka]
12.86±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
TL02-59 is a potent inhibitor of Fgr kinasea Src-family kinase expressed in myeloid cells and associated with acute myelogenous leukemia (AML). It exhibited an IC50 value of 0.03 nM for Fgr0.10 nM for related Src-family kinase Lynwith >1000-fold less potency for all other kinases tested. TL02-59 given orally in a mouse xenograft model of AML was able to eliminate spleen and peripheral blood leukemic cells and significantly reduce bone marrow engraftment. |
|
| Company Name: |
|
| Tel: |
|
| Website: |
www.sangon.com |
|